Invitae
Invitae Bets on Oncology Portfolio to Drive Growth as it Streamlines, Integrates Test Services
Premium
In the wake of last year's massive restructuring, Invitae is focused on developing its Personalized Cancer Monitoring product while integrating other oncology offerings.
JP Morgan Healthcare Conference, Day 3: Invitae, Bio-Rad, Bio-Techne, Opko
On the penultimate day of the conference, Invitae provided color on its recent decisions to pull out of certain businesses, while Bio-Rad talked about its clinical plans.
Invitae Preliminary Q4 Revenues in Line With Wall Street Estimate
Exited businesses and geographies led a year-over-year Q4 revenue decline, while annual revenues are expected to grow relative to 2021.
360Dx Top 30 Drops 37 Percent in 2022
All but one of the 30 companies in the list saw their share prices decline year over year with several firms' stock prices retreating more than 80 percent.
360Dx Top 30 Ends 2022 With 2 Percent Dip in December
Of the 30 companies in the index, nine saw their stock prices rise, while 21 firms' share prices decreased.
Sep 1, 2022
360Dx Top 30 Tumbles in August
Aug 1, 2022
360Dx Top 30 Rebounds in July After June Swoon
Jul 1, 2022
360Dx Top 30 Drops 5 Percent in June
May 3, 2022
Invitae Q1 Revenues Increase 19 Percent
Apr 21, 2022
Feb 24, 2022
Invitae Q4 Revenues Increase 26 Percent
Jan 4, 2022